Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab for CTC reduction in breast cancer bone metastasis
NCT01952054Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2015
- Primary completion
- Oct 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of denosumab in breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: The Effect of Denosumab in Reducing Circulating Tumor Cells (CTCs) at Week 4. Started Feb 2015; status: terminated.
02
Drugs
denosumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01952054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01952054.